- This is very positive news for Bio Vitos Pharma. This enables strong protection for our iron succinate product Succifer which we are developing and increases our future revenue potential. Via Double Bond Pharmaceutical (DBP), Bio Vitos Pharma also owns the rights to other identical patent applications that are under review for other important geographic markets, and we believe this is a very good sign for these applications as well, says Jesper Birgemo, CEO at Bio Vitos Pharma.

The clinical trials conducted by DBP show that iron succinate significantly improves iron absorption, iron saturation and iron storages in patients with heart failure and iron deficiency.

Iron succinate is a less expensive alternative to the successful product Ferinject (which - as the name suggests - is administered intravenously). In 2022, the global sales of Ferinject amounted to approximately USD 500 million.

For further information, contact:

Bio Vitos Pharma AB (publ)

Jesper Birgemo, CEO

Tel: +46(0) 70895 39 34

About Bio Vitos Pharma AB

Bio Vitos Pharma develops, produces, and commercializes iron succinate for the treatment of iron deficiency within the parent company as well as a service for close-to-patient detection of hemolysis in blood samples within the framework of a wholly owned subsidiary, Hemcheck Management AB. The company is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB is the Certified Adviser to the company.

Important information

This information is such information that Bio Vitos Pharma is required to disclose in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, for publication by the above contact person, for publication on December 20, 2023 at 07.30